5th Floor, Brigade Towers,
Financial District, Gachibowli,
Hyderabad - 500032,
India
Anti-hypertensive Drugs Market - Growth, Trends, and Forecast (2020 - 2025)
The market is segmented by Therapeutic Class and Geography
- ABOUT THIS REPORT
- Market Snapshot
- Market Overview
- Scope of the Report
- Key Market Trends
- Competitive Landscape
- Major Players
- TABLE OF CONTENTS
Market Snapshot
Study Period:
2016-2024
Base Year:
2019
Fastest Growing Market:
Asia Pacific
Largest Market:
North America
Major Players:
80% of our clients seek made-to-order reports. How do you want us to tailor yours?
Market Overview
The anti-hypertensive drugs market is expected to witness a CAGR of 4.5%, during the forecast period. Certain factors that are driving the market growth include increasing prevalence of hypertension, growing initiatives by private and government organizations, and rising awareness about hypertension.
The prevalence of hypertension has observed a significant rise over the past few years. Generally, blood pressure rises and falls throughout the day. However, it can damage one’s heart and result in health problems, if it stays high for a long time. High blood pressure is called hypertension. High blood pressure is the most harmful factor when it comes to the risk of heart disease and stroke, which is the leading cause of death in the United States. According to the CDC (Centers for Disease Control and Prevention), about 75 million American adults (32%) have high blood pressure (hypertension), but only about half (54%) of people with high blood pressure have their condition under control. High blood pressure was a primary and contributing cause of death for more than 410,000 American citizens, in 2014. CDC also states that high blood pressure costs the nation USD 48.6 billion every year. This total includes the medications to treat high blood pressure, cost of health care services, and missed days of work.
However, even though most blood pressure medicines are easy to administrate, almost all medicines show certain side effects. Some common side effects of the antihypertensive medicines include cough, diarrhea or constipation, dizziness or lightheadedness, erection problems, feeling nervous, feeling tired, weak, drowsy, or a lack of energy, headache, skin rash, nausea or vomiting, and weight loss or gain without trying. These various side effects associated with the antihypertensive drugs are expected to hinder the growth of the market, over the forecast period.
Scope of the Report
Antihypertensive drugs are referred to as a class of drugs that are used in treating hypertension (high blood pressure). There are many classes of antihypertensive drugs, which have the ability to lower blood pressure by different means, and thus, prevent the complications associated with high blood pressure, including stroke and myocardial infarction.
| Therapeutic Class | |
| Diuretics | |
| Angiotensin Converting Enzyme (ACE) Inhibitors | |
| Angiotensin Receptor Blockers (ARBs) | |
| Beta Blockers | |
| Alpha Blockers | |
| Renin Inhibitors | |
| Calcium Channel Blockers | |
| Other Therapeutic Classes |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Report scope can be customized per your requirements. Click here.
Key Market Trends
Diuretics is Expected to Hold a Significant Market Share in the Therapeutic Class
Thiazide diuretics are the cornerstone of treatment for hypertension in most patients. Hydrochlorothiazide is the most commonly used thiazide diuretic in the United States. The Joint National Committee on the prevention, detection, evaluation, and treatment of high blood pressure recommends thiazide-type diuretics to be one of the preferred drug treatments for hypertension, whether used on its own or along with other antihypertensive drugs, such as calcium channel blockers. Moreover, it was also noted that more than one-third of the adults affected by hypertension were reported to take diuretics.
To understand key trends, Download Sample Report
North America Dominates the Market and is Expected to do Same during the Forecast Period
According to the AHA (American heart association), 74.9% of hypertension patients are currently undergoing treatment, and only 52.2% of patients have it under control. AHA projection shows that by 2030, about 41.4% of adults in the United States are expected to have hypertension. The demand for prompt and accurate diagnosis, and treatment of hypertension, identifying people predisposed to the disease, presence of technically advanced healthcare infrastructure, and management of the prognosis of the disease are some of the key market drivers of the North American anti-hypertension market.
To understand geography trends, Download Sample Report.
Competitive Landscape
The anti-hypertensive drugs market is highly competitive and consists of a number of major players. Companies, like Astrazeneca PLC, Boehringer Ingelheim, Daiichi Sankyo Company Limited, Johnson & Johnson Ltd, Lupin Limited, Merck & Co. Inc., Novartis AG, Pfizer Inc., Ranbaxy Laboratories Limited, and Sanofi SA, among others, hold the substantial market share in the anti-hypertensive drugs market.
Table Of Contents
1. INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Hypertension
4.2.2 Growing Initiatives by Private and Government Organizations
4.2.3 Rising Awareness about Hypertension
4.3 Market Restraints
4.3.1 Multiple Major Drug Patent Expiration
4.3.2 Side-effects of Treatment Options
4.3.3 Rise in Non-pharmacological Therapy
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 Therapeutic Class
5.1.1 Diuretics
5.1.2 Angiotensin Converting Enzyme (ACE) Inhibitors
5.1.3 Angiotensin Receptor Blockers (ARBs)
5.1.4 Beta Blockers
5.1.5 Alpha Blockers
5.1.6 Renin Inhibitors
5.1.7 Calcium Channel Blockers
5.1.8 Other Therapeutic Classes
5.2 Geography
5.2.1 North America
5.2.1.1 United States
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 Germany
5.2.2.2 United Kingdom
5.2.2.3 France
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia-Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South korea
5.2.3.6 Rest of Asia-Pacific
5.2.4 Middle East & Africa
5.2.4.1 GCC
5.2.4.2 South Africa
5.2.4.3 Rest of Middle East & Africa
5.2.5 South America
5.2.5.1 Brazil
5.2.5.2 Argentina
5.2.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Astrazeneca PLC
6.1.2 Boehringer Ingelheim
6.1.3 Daiichi Sankyo Company Limited
6.1.4 Johnson & Johnson Ltd
6.1.5 Lupin Limited
6.1.6 Merck & Co. Inc.
6.1.7 Novartis AG
6.1.8 Pfizer Inc.
6.1.9 Ranbaxy Laboratories Limited
6.1.10 Sanofi SA
*List Not Exhaustive7. MARKET OPPORTUNITIES AND FUTURE TRENDS
**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments
LINKS
JOIN US
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination.
Interested? Please email us
[email protected]© 2020. All Rights Reserved to Mordor Intelligence.